Marlene M Speth1, Lloyd P Hoehle2, Katie M Phillips2, David S Caradonna3, Stacey T Gray2, Ahmad R Sedaghat4. 1. Klinik für Hals-, Nasen-, Ohren- Krankheiten, Hals-und Gesichtschirurgie, Kantonsspital Aarau, Switzerland. 2. Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts; Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. 3. Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts; Division of Otolaryngology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 4. Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts; Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Division of Otolaryngology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Otolaryngology and Communications Enhancement, Boston Children's Hospital, Boston, Massachusetts. Electronic address: ahmad_sedaghat@meei.harvard.edu.
Abstract
BACKGROUND: Previous work has shown that the symptoms of chronic rhinosinusitis (CRS) differentially associate with decreased general health-related quality of life (QOL). OBJECTIVE: We sought to determine whether longitudinal changes in different types of CRS symptomatology lead to correspondingly different magnitude changes in general health-related QOL. METHODS: Prospective observational study of 145 patients undergoing medical management for CRS. Chronic rhinosinusitis symptom severity was measured using the 22-item Sinonasal Outcome Test (SNOT-22) and associated nasal, sleep, ear/facial discomfort, and emotional subdomains of the SNOT-22. General health-related QOL was measured using the 5-dimensional EuroQoL questionnaire's visual analog scale (EQ-5D VAS). These data were collected at 2 time points: at enrollment and at a subsequent follow-up visit within the next 2 to 6 months. Associations were sought between the changes in SNOT-22 and EQ-5D VAS. RESULTS: The change in SNOT-22 was associated with change in EQ-5D VAS (adjusted linear regression coefficient [β] = -0.37, 95%CI: -0.51 to -0.24, P < .001). The change in EQ-5D VAS was only associated with changes in the sleep (adjusted β = -0.42, 95% confidence interval [95%CI]: -0.81 to -0.04, P = .034) and ear/facial discomfort (adjusted β = -1.00, 95%CI: -1.89 to -0.10, P = .031) subdomains but not nasal (adjusted β = -0.12, 95%CI: -0.52 to 0.28, P = .564) or emotional (adjusted β = -0.17, 95%CI: -1.83 to 1.49, P = .840) subdomains. CONCLUSION: Changes in the severity of sleep and ear/facial discomfort symptoms associate most greatly with the change in general health-related QOL that CRS patients experience during routine medical management. Reduction of these extranasal symptoms of CRS may therefore lead to the greatest improvement in general health-related QOL.
BACKGROUND: Previous work has shown that the symptoms of chronic rhinosinusitis (CRS) differentially associate with decreased general health-related quality of life (QOL). OBJECTIVE: We sought to determine whether longitudinal changes in different types of CRS symptomatology lead to correspondingly different magnitude changes in general health-related QOL. METHODS: Prospective observational study of 145 patients undergoing medical management for CRS. Chronic rhinosinusitis symptom severity was measured using the 22-item Sinonasal Outcome Test (SNOT-22) and associated nasal, sleep, ear/facial discomfort, and emotional subdomains of the SNOT-22. General health-related QOL was measured using the 5-dimensional EuroQoL questionnaire's visual analog scale (EQ-5D VAS). These data were collected at 2 time points: at enrollment and at a subsequent follow-up visit within the next 2 to 6 months. Associations were sought between the changes in SNOT-22 and EQ-5D VAS. RESULTS: The change in SNOT-22 was associated with change in EQ-5D VAS (adjusted linear regression coefficient [β] = -0.37, 95%CI: -0.51 to -0.24, P < .001). The change in EQ-5D VAS was only associated with changes in the sleep (adjusted β = -0.42, 95% confidence interval [95%CI]: -0.81 to -0.04, P = .034) and ear/facial discomfort (adjusted β = -1.00, 95%CI: -1.89 to -0.10, P = .031) subdomains but not nasal (adjusted β = -0.12, 95%CI: -0.52 to 0.28, P = .564) or emotional (adjusted β = -0.17, 95%CI: -1.83 to 1.49, P = .840) subdomains. CONCLUSION: Changes in the severity of sleep and ear/facial discomfort symptoms associate most greatly with the change in general health-related QOL that CRSpatients experience during routine medical management. Reduction of these extranasal symptoms of CRS may therefore lead to the greatest improvement in general health-related QOL.
Authors: Marlene M Speth; Katie M Phillips; Lloyd P Hoehle; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: Eur Arch Otorhinolaryngol Date: 2019-07-19 Impact factor: 2.503
Authors: Rehab Talat; Katie M Phillips; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: Eur Arch Otorhinolaryngol Date: 2019-07-15 Impact factor: 2.503
Authors: Claire Gleadhill; Marlene M Speth; Isabelle Gengler; Katie M Phillips; Lloyd P Hoehle; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: Eur Arch Otorhinolaryngol Date: 2020-08-04 Impact factor: 2.503
Authors: David T Liu; Katie M Phillips; Firas A Houssein; Marlene M Speth; Gerold Besser; Christian A Mueller; Ahmad R Sedaghat Journal: Laryngoscope Date: 2022-03-30 Impact factor: 2.970